ERT.jpg

Clario (formerly ERT)

eClinical Solutions for the Pharmaceutical Industry

Clario delivers the leading endpoint technology solutions for clinical trials. The company fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives.

Company Background

  • Experience gained from over 19,000 clinical trials delivered in support of 870 regulatory approvals
  • Trusted partner to pharmaceutical and biotechnology companies
  • Unique combination of technology, scientific and therapeutic expertise with digital innovation and a strong focus on customer service

Vision & Outlook

Unlocking better evidence and transforming patients’ lives by driving further expansion of its operational capabilities

Continue to deliver best-in-classs technology to enable richest clinical evidence

Boost diversity among patients in clinical trials, within its own inclusive workplace and among its suppliers

Highlights & Updates

  • Nordic Capitals re-invested alongside Astorg and Novo through Fund IX in 2020
  • Merger with Bioclinica forming the combined company named Clario in 2021
  • Awarded top workplace recognition for D&I by Energage and committed to net zero climate reduction target aligned with SBTi in 2022
Clario Logo

SECTOR

Healthcare

Technology & Payments

REVENUES 2021

EUR 780 million

EMPLOYEES

6,010

OWNERSHIP

Fund IX

HEAD OFFICE

US

INVESTMENT DATE

2020

MANAGEMENT

Chris Fikry

CEO

Mike Bonello

CFO

CHAIRPERSON

Chris Viehbacher

Chair

RESPONSIBLE ADVISORS

Raj Shah

Partner | Head of Healthcare

Daniel Berglund

Partner